Prokaryotics receives Notice of Allowance from U.S. Patent and Trademark Office for two patents covering novel compounds which restore the efficacy of commonly used β-lactams against MRSA

Union, NJ — June 9, 2021 — Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has received a Notice of Allowance for two patents, each covering a distinct series of novel compounds for both composition of matter and use as adjuvants to restore the efficacy of commonly used β-lactams against the dangerous superbug MRSA. These patents are expected to issue in the US in 4Q2021.

These patents represent an important asset and a key milestone, as our program to identify an agent to combat Gram-positive resistant strains continues to progress toward identification of a development candidate. These cases provide a broad base of protected intellectual property for our medicinal chemistry effort, and we intend to follow up with a series of narrower applications to strengthen our position as we transition toward early clinical development.
-- Sherman Tim Waddell, Ph.D., VP and Head of Chemistry at Prokaryotics.

About Multi-Drug Resistant Infections
The relentless advance of antibiotic drug resistant bacteria has raised concerns whether within the next 2-3 decades we could be facing a ‘pre-antibiotic era’ where existing antibiotics will become largely ineffective in treating serious and life-threatening infections. Indeed, the World Health Organization has projected that the impact on human health and economic costs associated with antibiotic drug resistance will rival that of global warming. New classes of antibiotics with novel mechanisms of action are urgently needed to combat the growing threat of multi-drug resistant bacteria.

About Prokaryotics, Inc.
Prokaryotics, Inc. is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes that target serious multi-drug resistant bacterial infections. Prokaryotics leverages a deep knowledge of bacterial physiology, innovative screening strategies, and scientific excellence necessary to discover and develop new classes of antibiotics targeting outer membrane biogenesis – the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics.

Media Contact:
Pamela Demain
908 737-1922 x120
pdemain@prokaryotics.com